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The Role of Arachidonic Acid Metabolites in
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The elucidation of the reactions le.iding to both therelease of arachidonic acid from membrane-
bound phospholipids and its subsequent metabolic
conversion into potent, biologically active lipids are
landmark discoveries in the areas of physiology and
inflammation. Historically, early investigations in this
field were directed at isolating und characterizing the
diverse metabolites of the cyclooxygenation of ara-
chidonit acid. Kurzockand Lieb,' Goldblatt,^ and von
Euler' contributed seminal observations regarding the
biologic activity of an acidic lipid believed to be syn-
thesized by the prostate gland, hence the term pros-
taglandin. Later, Bergstrom and co-workers'*^ dem-
onstrated that prostaglandins represent a spectrum oi
related lipids with a similar chemical structure. The
major impetus to study the biochemical role and phar-
macologit manipulation of arachidonic acid metabo-
lism, with regard to inflammation, was provided by
Vane,'' with the observation that aspirin and aspirin-
like drugs could suppress prostagl.indin synthesis and
regulate inflammatory reactions. The foundation for
subsequent work concerning produc ts of the lipoxy-
genase pathway was laid by Feldberg and Kellaway^
in 19^8. In tbese early experiments, they demonstrated
that the perfusate of cobra venom-treated lungs con
tained both a lysolecithin-like compound and a com-
pound that generated a smooth muscle contracting
factor termed slow reacting substance" (SRS). Nearly
30 years later, these same SRS-type compounds were
found to play a key role in immediate hypersensitivity
reactions, especially asthma." SRS of anaphylaxis (SRS-
A) is usually referred to as an immunologically released
SRS and now is known to consist oi leukotriene C4,
D4. and E4. The structural work and complete chemical
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characterization of SRS-A was reported in 1979.'' At
the same time that the structure of SRS-A was reported,
Borgeat and Samuelsson'" isolated a dihydroxy me-
tabolite of arachidonit acid formed by rabbit leuko-
cytes and subsequently named this compound leu-
kotriene B .̂ The importance of arachidonic acid me-
tabolites in diverse systems and the contribution of
key scientists was recognized in 1982 with Nobel prizes
being awarded to Drs. Bergstrom, Samuelsson, and
Vane.
In addition to the studies by these Nobel laureates,
numerous investigators have demonstrated the ability
oi arachidonic acid metabolites to participate in the
regulation of diverse physiologic systems. This is truly
exemplified by the key rote these ubiquitous fatty acids
play in dictating the function of cells that are involved
in acute and chronic immune reactions. Products from
both the cyclooxygenase and lipoxygenase pathway
{Fig. 1) are known to be synthesized during immune-
inflammatory responses and can influence the out-
come of various phlogistic episodes. There is little
doubt that LTB4 and many of the hydroxylated eicosa-
tetraenoic acids (HETEs) are important in acute-neu-
trophil-mediated reactions. These lipoxygenase prod-
ucts appear to play a central rote in the initiation and
maintenance of acute inflammation by causing leu-
kocyte chemotaxis," aggregation,'^ lysosom.il enzyme
release,'^ and the production of oxygen metabolites.'"'
Conversely, specific cyclooxygenase-derived metab-
olites (PGE, and PCIjJ have been shown to suppress
many of the above leukocytic functions.''^ '"Thus, the
products of the two major pathways of arachidonic
acid metabolism have been hypothesized to function
in a yin-yang manner as the inflammatory reaction is
initiated and eventually resolved. Although the current
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FIC. 1. Cascade of arachidonic acid metabolites synthesized via the cycltMixygenase and lipoxygenase pathways.
literature concerning arachidonate metabolites in
neutrophil-mediated reaction is voluminous, an ex-
haustive review examining the participation of these
various lipids in acute inflammation is beyond the
scope of this article. The goal of this review is to sum-
marize and expand our current understanding of the
biochemical, biologic and clinical aspects of arachi-
donic acid metabolic products in macrophage- and
lymphocyte-mediated reactions.
Metabolism of Arachidonic Acid by Mononuclear
Phdgocytic Cells
The importance of arachidonic acid metabolites
synthesized by mononuclear phagocytes is suggested
by the bigh percentage of this fatty acid found ester-
ified in the number two position of membrane phos-
pbolipids. Arachidonic acid was found to constitute
approximately 25% of all esterified membrane fatty
acids in various mononuclear phagocytic cell prepa-
rations,'"''' while neutrophil membranes contained less
than 3% esterified arachidonic acid.-'" Phosphoiipid
analysis of macrophage membranes indicates that the
majority of arachidonic acid is found at position two
of phosphatidylcholine.'' The functional importance
of this particular phosphoiipid as a reservoir of mac-
rophage aracbldonic acid is shown clearly by the re-
duction in arachidonic acid metabolites by macro-
phages treated with inhibitors of phosphatidylcholine
synthesis," and the dramatic loss of arachidonic acid
from phosphatidylcholine with a concomitant appear-
ance of metabolites by stimulated macrophages. It is
important to note that the mobilization of arachidonic
acid is dependent upon the activation of pbospholi-
pases by specific receptor-ligand interactions.^^ This
concept is critical, since investigations have demon-
strated that phospholipases may be maintained as
separate pools within the macrophage.''' One pool ap-
pears to be associated with intracellular lysosomes and
triggered by a phagocytic stimulus and an additional
pool appears to be associated with the plasmalemma
and activated by membrane perturbation. In additional
studies,^ '̂ the activation of phospholipase and the mo-
bilization of different pools of substrate arachidonic
acid have been shown to result in different types of
metabolic products. Membrane perturbants, such as
phorbol esters^" and lipopolysaccharide,'^^ selectively
stimulated the cyclooxygenation of arachidonic acid,
while zymosan triggered both metabolic pathways.
As detailed above, the metabolism of arachidonic
acid occurs by two major routes. The major metabolites
synthesized by macrophages via the cyclo-oxygenase
pathway are prostaglandin E2 (PGE2) and prostacyclin
(PGI2), while thromboxane TXA2 (and its stable metab-
otite, TXB2) and prostaglandin F2J have also been
identified.-^^ Macrophages have a significant ability to
metabolize arachidonic acid through the lipoxygenase
pathway with the concomitant synthesis of mono-
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HETEs and leukotrienes. Although mono-HETEs (pre-
dominantly 12-HETE) appear to be the most abundant
of the macrophage-derived lipoxygenase products, the
leukotrienes are the best understood. Various cultured
macrophage preparations have been shown to syn-
thesize a number of biologic ally active lipids, including
conjugated Irienes.^^ '" While speculations abound
concerning the clinical role these leukotrienes play in
human disease, save for certain types of asthma, the
exact role of these lipoxygenase products remains en-
igmatic.
There is little doubl that mononuclear phagocytic
cells possess a unique capability to metabolize ara-
chidonic acid to numerous metabolic end points. This
prolific metabolic capacity of macrophages has lead
numerous investigators to study those factors that dic-
tate the various facets of macrophage arachidonic acid
metabolism. The quantitative and qualitative aspects
of metabolite formation clearly is a function of both
the exogenous stimulus and the state of macrophage
activation. The latter is defined by a variety of bio-
chemical and physiologic criteria. Much of the current
understanding of macrophage arachidonate metabo-
lism stems from studies using different populations of
murine peritoneal macrophages. These populations
include both resident or resting macrophages and
macrophages elicited by either an irritant, such as
thioglycollate, or an immunologic challenge, such as
heat-killed organisms of Corynebacterium or Myro-
bacterium. The diverse nature of the different cell pop-
ulations is reflected in tbe different arachidonic acid
metabolites tbese cells synthesize. Investigations using
resting peritoneal macrophage have demonstrated
that, in the unstimulated state, these cells release min-
imal metabolic products. If these resident macrophages
are given an exogenous source of arachidonic acid in
the absence of other stimuli, approximately 40% of
the arachidonic acid is incorporated into phospholip-
ids, while the remainder is metabolized to mono-HETEs
and the stable analogue of PGI2, 6-Keto-PGF,,,. The
metabolism of endogenous arachidonic acid (phos-
pholipid boutxi) following a phagocytic challenge of
zymosan or immune complexes was found to result in
the formation of PGE,, 6-Keto-PGF,„, and LTC4." In
contrast, elicited peritoneal macrophages have a di-
minished capability to synthesize arachidonic acid
metabolites, Mocrophages elicited with either an irri-
tant or immunologic challenge incorporate more ex-
ogenous arachidonic acid and release significantly less
metabolites. In addition, zymosan-treated-elicited
macrophages convert endogenous arachidonic acid to
only 10% of the metabolites formed by similarly
treated resting cells.*^ A possible mechanism for the
above observations may be due to an increase in the
acylation of arachidonic acid or decrease in the de-
acylation by the activated macrophage populations.
The absolute amounts of arachidonic acid metabolites
released by various resting and elicited peritoneal
macrophage populations in the presence and absence
of a stimulus are shown in Table 1.
In addition to the state of macrophage activation,
the amount and variety of metabolites are dependent
upon the particular stimulus under study. As discussed
above, synthesis of aracbidonic acid metabolites by
both the cyclooxygenase and lipoxygenase pathways
can be observed when macrophages or monocytes are
given a zymosan phagocytic challenge. Interestingly,
phagocytosis itself does not appear to be directly re-
sponsible for product generation, since latex bead
phagocytosis did not cause prostaglandin synthesis.^'
The most important step in phagocytosis-induced ar-
achidonate metabolism appears to be receptor-ligand
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Fic. 2. HPLC analysis oi ^H-ardchidonic acid metaboiites syn
thesized by resident murine peritoneal matrophages slimulated with
either 10 fig/ml LPS {A) or 250 *ig/ml zymosan (B).
interaction involving specific receptors." Macrophages
treated with compounds that suppress lysosome-pha-
gosome fusion and block phagocytosis still produced
normal levels of PCEj when challenged with zymosan.
A number of soluble stimuli that can induce membrane
perturbation, independent of specific receptor inter-
action, also have been shown to stimulate arachidonic
acid metabolism, including lipopolysaccharide (LPS),
phorbot esters, and colchicine. As shown in Figure 2,
the selectivity of metabolite formation varies dramat-
ically with the stimulus under study. The membrane
perturbant LPS resulted in the synthesis of only cyclo-
oxygenase products, while zymosan induced the syn-
thesis of both cyclooxygenase and lipoxygenase-de-
rived metabolites. It is important to reiterate that the
metabolism of arachidonic acid by mononuclear
phagocytic cells is dependent upon a multitude of in-
dependent factors: (1) the anatomic location of the
macrophage, (2) the state of macrophage activation,
(3) the stimulus under study, (4) whether the cells are
adherent, and (5) the presence of free or membrane-
bound arachidonic acid.
Regulation of Immune Cell Function by Metabolites
of Arachidonic Acid
Experimental evidence supports the view that var-
ious metabolites of arachidonic acid can exert pro-
found modulatory effects on cells involved in immune-
inflammatory responses. The robust ability of certain
macrophage populations to synthesize diverse arachi-
donic acid metabolites implicates these cells in the
immunoregulation of immune reactions.^* It is well es-
tablished that macrophages can synthesize rather large
quantities of PGE2. The ability of PCE to promote local
vasodilitation and edema'^ has led many clinicians to
presume this prostaglandin to be proinflammatory;
however, current experimental evidence suggests that
PGE2 and PGI2 possess dramatic suppressive activity
in macrophage- and lymphocyte-mediated reactions.
In vitro. PGE2 has been shown to suppress a number
of critical lymphocyte functions including B and T cell
proliferation,^^^^^ natural killer cell activity,'^ and cell-
mediated cytotoxicity.^"^ With regard to the production
of lymphocyte-derived soluble mediators, Gordon et
al.**" and Bray et al."' have demonstrated that PGE2 can
suppress lymphokine production, as monitored by
macrophage migration inhibition. In addition, Baker
and co-workers"- and Rappaport and Dodge'" have
shown that PGE2 is efficacious in suppressing the pro-
duction of interleukin-2 (IL-2). In the latter study,
treatment of preparations with cyclooxygenase inhib-
itors was shown to augment the production of IL-2,
thus providing support that endogenous PGE2 is in-
volved in regulating tbe production of lymphocyte
mediators. Prostaglandins also may exert an immu-
nosuppressive effect by inducing the activity of sup-
pressor T cells.'"' A supporting study suggests that PGE;
inhibits mitogen-induced proliferation by inducing a
short-lived radiosensitive suppressor T cell;"^ upon ac-
tivation with PGE2, this lymphocyte population may
suppress the proliferative response of the remaining
lymphocytes.
It is becoming increasingly apparent that not only is
the function and activity of lymphocytes regulated by
prostaglandins, but the macrophage itself appears to
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be modulated by various arachidonic acid metabolites.
Prostaglandin E2 has been shown to regulate macro-
phage oxygen metabolite production,'"' tumoricidal
activity,""" and macrophage proliferation."" Of particular
interest is tbe suppressive effect of PGE2 on the pro-
duction of macrophage- and monocyte-derived sig-
nals necessary to activate lymphocytes. These studies
include the inhibition of macrophage interleukin-1 (IL-
1) production,^** as well as the suppression of lympho-
kine-induced macrophage membrane l-region asso-
ciated (la) antigens."''^" The suppressive effect of PGE2
on macrophage la antigen expression appeared to
possess a high degree of specificity since neither Fc
receptor expression nor H-2K expression was altered.
The in vivo suppression of la antigen expression would
dramatically alter the antigen-presenting capability of
macrophages and inhibit lymphocyte activation. We
recently have demonstrated that IL-1, an important
macrophage-derived signal witb profound effects on
lymphocyte-mediated reactions, can be regulated by
a self-induced inhibitor, PGE2.̂ *' As shown in Table 2,
PGE2 can suppress IL-1 production by LPS-stimulated
macrophages in a dose-dependent manner. Further-
more, the cyclooxygenase inhibitor, indomethacin,
demonstrated a dose-dependent augmentation in IL-
1 production by LPS-stimulated macrophages. These
studies suggest that endogenous PGE2 can serve as a
mechanism to regulate the production of an important
lymphocyte-activating factor.
Regulation of tn Vivo Macrophage- and
Lymphocyte-dependent Reactions by Metabolites of
Arachidonic Acid
Considering the large body of evidence showing that
both macrophages and lymphocytes are targets for the
regulatory effects of arachidonic acid metabolites, it is
not surprising that numerous in vivo models have
demonstrated that the development of chronic in-
flammation can be altered by these metabolites. Ani-
mal models of adjuvant-induced arthritis,'^' pulmonary
hypersensitivity granulomas," and autoimmune ne-
phritis^* all have been demonstrated to be susceptible
to PGE-mediated suppression. The initial impetus to
study the therapeutic effect of prostaglandins stemmed
from the observation that these biologically active lip-
ids, with in vitro suppressive activity, commonly were
found in inflammatory exudates. Prostaglandin E2
treatment first was shown to be effective in suppressing
the macrophage- and lymphocyte-mediated reactions
that result in the development of the polyarthritic re-
sponse. In an extension of these early studies, inves-
tigations have shown that the polyarthritic response
can be suppressed by the oral administration of a stable
TABLE 2. Dose-dependent Suppression of IL-1 Pf<}ductiiin hy LPS-
slirr\ulaled Murine Peritoneal Mjcrophage by PCf^ and
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' IL-1 was assayed using a thymocyte proliferation assay in the
presence of dialyzed macrophdge supernatant and suboplinial doses
of PHA.
PGE, analogue, 15-methy!-PGEi." The oral activity of
this compound most likely resides in its stability due
to the protection of the 15-hydroxyl group from the
action of the J5-hydroxy-prostaglandin dehydroge-
nase. The stable analogue of PGEi also was found to
be efficacious in the treatment of murine systemic lu-
pus erythematosus-like syndrome."^' Both NZB/NZW
mice and MRL/1 mice responded to prostaglandin
therapy with a decrease in clinical nephritis and mor-
tality. The therapeutic activity of PGE compounds in
tbese animals is most likely due to the preservation of
cell-mediated immunity by dictating the appropriate
number of T and B cells, since diminished T-lympho-
cyte populations and increased B-lymphocyte func-
tions are an early index of this disease. Additional
studies have demonstrated the ability of PGE to sup-
press the normal progression of the nephritic response
in animal whose disease was established at the onset
of treatment."̂ "̂  Recent studies have examined the in
vivo activity of prostaglandins on the development of
foreign-body- and delayed-type hypersensitivity gran-
ulomatous inflammation. The delayed-type hypersen-
sitivity granuloma involves a highly active T-lympho-
cyte-mediated lesion, whose development and regu-
lation is controlled by macrophage-lymphocyte
interactions, while the foreign body reaction is less
vigorous and does not involve T ceil sensitization. In-
vestigations have demonstrated that prostaglandins can
alter the delayed-type hypersensitivity, but not the
foreign-body response." In this study, PGE treatment
was shown to suppress the elicitation of the granulo-
matous response and inhibit the induction of sensitized
lymphocytes, whereas PGF .̂, augmented the eli-
citation phase of the response. To further elucidate
the modeof PGE-induced suppression of the delayed-
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lymphocyte
activating tactor
Fic. 3. Synopsis ol the molecular signals that are responsible for
the normal communications that occur between macrophages and
lymphocytes. Each of the t hemicat signals are potential targets for
the potontiation or suppression of chronit immune responses by
specific melaboiites of arachidonic acid.
type hypt^rsensitivity lesion, the kinetics of the ap-
[jcarance of la-positive macrophages in developing le-
sions was studied. Proslaglandin E treatment dramat-
irally suppressed granuloma macrophage la expression
throughout the study period,^" at times by as much as
60%. On the contrary, PGF2,,, was shown to enhance
granuloma macrophage la antigen expression during
the early phase of granuloma development. The alter-
ation in the percentage of ia positive granuloma mac-
rophages was shown to parallel the degree of cellular
infiltrate. Neither PGF .̂, nor PCE had an effecl on the
low levels of la antigen being expressed on the mac-
rophages recovered from the foreign-body lesions.
These observations may prove to be very important in
the control of noninfectious granulomatous inflam-
mation, since la antigen expression by macrophages
is a critical signal for antigen presentation and T-iym-
phocyte proliferation.
Summary
Numerous investigations support the theory that ar-
achidonic acid metabolites play a critical role in dic-
tating the progression of chronic immune reactions.
With regard to macrophage-mediated inflammatory
responses, enzymatic oxygenation of arachidonic acid
via the lipoxygenase or cyclooxygenase pathway can
result in the production of compounds that may po-
tentiate or suppress the inflammatory lesion. We re-
cently have presented data demonstrating that lipox-
ygenase derived leukotriene B4 and C4 can induce Ihe
release of IL-1 by macrophages, while PGEj and PGIj
can suppress the production of IL-1,-'*' Macrophages
are central to the induction of immune responses and
the progression of chronic inflammatory reactions.
Therefore, an understanding of th<> role that macro-
phage-derived arachidonic acid metabolites play in the
initiation, maintenance, and resolution of chronic im-
mune responses is essential. As shown in Figure 3,
there are a number of chemical signals that occur be-
tween macrophages and lymphocytes that are critical
for immune cell communication. The investigations
described above have demonstrated that the macro-
phage may regulate the production and expression of
any or all of these signals, such that the inflammatory
response is potentiated, sustained, suppressed, or re-
solved. A better comprehension of the activity of these
potent arachidonate derivatives will undoubtedly aid
in the therapeutic manipulation of inflammatory dis-
ease.
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